Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine, DongShin University, Naju City, 58245, Republic of Korea.
Department of Acupuncture and Moxibustion Medicine, Semyung University Korean Medicine Hospital in Chungju, Chungju, 27429, Republic of Korea.
Trials. 2021 Mar 4;22(1):184. doi: 10.1186/s13063-021-05135-6.
Dangguixu-san (DS), a herbal extract, is widely used in Korean medicine to treat pain and swelling caused by ankle sprain. However, there is insufficient evidence regarding the effects of DS on ankle sprains. Accordingly, we assessed the efficacy and safety of DS for the treatment of acute lateral ankle sprain (ALAS).
This study was a multicenter (two Korean hospitals), randomized, double-blind, placebo-controlled, parallel-arm clinical trial with a 1:1 allocation ratio that included a per-protocol analysis and sub-analysis based on symptom severity. Forty-eight participants (n = 28 at Semyung University Korean Medicine Hospital in Chungju; n = 20 at DongShin University Gwangju Korean Medicine Hospital) with grade I or II ALAS that occurred within 72 h before enrollment were randomized to a DS (n = 24) or placebo (n = 24) group. Both groups received acupuncture treatment once daily for 5 consecutive days and the trial medication (DS/placebo capsule) three times a day for 7 consecutive days. Primary (visual analog scale [VAS] scores for pain) and secondary (Foot and Ankle Outcome Scores [FAOS], edema, and European Quality of Life Five-Dimension-Five-Level Scale [EQ-5D-5L] scores) outcome measures were recorded at baseline (week 0), the end of the intervention (week 1), and 4 weeks after treatment completion (week 5).
Forty-six participants completed the trial (n = 23 each). Changes in VAS scores, FAOS Symptom/Rigidity, and FAOS Ache from week 1 to week 5 showed significant differences between the two groups. Sub-analyses showed significant differences in changes of FAOS Ache (week 0 to week 5) and VAS scores, total FAOS, and EQ-5D-5L scores (week 1 to week 5) between the two subgroups (grade II). There were no adverse events and significant negative changes in clinical laboratory parameters in both groups.
Overall, the results of this study are in favor of DS combined with acupuncture and suggest that DS combined with acupuncture is a safe treatment with positive long-term effects in terms of pain reduction and symptom alleviation in patients with grade I or II ALAS.
Clinical Research Information Service KCT0002374 . Registered on July 11, 2017; retrospectively registered.
当归芍药散(DS)是一种草药提取物,在韩国医学中广泛用于治疗踝关节扭伤引起的疼痛和肿胀。然而,关于 DS 对踝关节扭伤的疗效证据不足。因此,我们评估了 DS 治疗急性外侧踝关节扭伤(ALAS)的疗效和安全性。
这是一项多中心(两所韩国医院)、随机、双盲、安慰剂对照、平行臂临床试验,采用 1:1 分配比,包括意向治疗分析和基于症状严重程度的亚组分析。48 名参与者(忠州顺天大学韩医医院 28 名;光州东新大学韩医医院 20 名)在入组前 72 小时内发生 I 或 II 级 ALAS,随机分为 DS(n=24)或安慰剂(n=24)组。两组均接受每日一次的针刺治疗 5 天,并连续 7 天每日服用三次 DS/安慰剂胶囊。主要(疼痛视觉模拟评分[VAS])和次要(足踝结局评分[FAOS]、肿胀和欧洲生活质量五维五分量表[EQ-5D-5L])结局指标在基线(第 0 周)、干预结束时(第 1 周)和治疗完成后 4 周(第 5 周)记录。
46 名参与者完成了试验(每组 23 名)。第 1 周至第 5 周 VAS 评分、FAOS 症状/僵硬和 FAOS 疼痛的变化在两组间差异有统计学意义。亚组分析显示,两组间 FAOS 疼痛的变化(第 0 周至第 5 周)以及 VAS 评分、总 FAOS 和 EQ-5D-5L 评分(第 1 周至第 5 周)差异有统计学意义。两组均无不良事件,临床实验室参数无显著负向变化。
总体而言,本研究结果倾向于 DS 联合针刺,提示 DS 联合针刺治疗 I 或 II 级 ALAS 患者安全有效,可长期减轻疼痛和缓解症状。
临床研究信息服务 KCT0002374。于 2017 年 7 月 11 日注册;回顾性注册。